Search This Blog

Friday, September 1, 2023

Turnstone Business Update

 

  • Successfully closed upsized IPO, raising $88 million in gross proceeds to continue advancing pipeline of Selected TIL Therapy programs

  • Cash position expected to fund operations into second quarter of 2025

  • Two Phase 1 clinical trials of lead program, TIDAL-01, in several solid tumor Indications ongoing

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.